Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

JAK-STAT is a rational drug target in myelofibrosis (MF) given its association with JAK2/MPL mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of CYT387, a potent JAK1/2 inhibitor, in patients with high- or intermediate-risk primary or post-polycythemia vera/ess...

Full description

Saved in:

Bibliographic Details
Main Authors:	Pardanani, A, Laborde, R R, Lasho, T L, Finke, C, Begna, K, Al-Kali, A, Hogan, W J, Litzow, M R, Leontovich, A, Kowalski, M, Tefferi, A
Format:	Artigo
Language:	Inglês
Published:	Nature Publishing Group 2013
Subjects:	Original Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3677140/ https://ncbi.nlm.nih.gov/pubmed/23459451 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.71
Tags:	Add Tag No Tags, Be the first to tag this record!

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

Similar Items